Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 12Lymphoid 7Head & Neck 5Thoracic 4Gynecologic 4Genitourinary 4Gastrointestinal 4CNS 4Plasma cell 3Other hematologic neoplasm 3Endocrine 3Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2NET 2Dermatologic 2

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Standard of Care 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Gemcitabine 6Cyclophosphamide 6Capecitabine 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Surveys and Questionnaires 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fluorodeoxyglucose F18 × Tumor-Agnostic × 90 days × Clear all
NCT02130492 2026-05-15

A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)

Weill Medical College of Cornell University

Phase 1/2 Suspended
30 enrolled
Tumor-Agnostic

Neoplasms

NCT06630845 2026-04-03

Comparison of Whole Body DWI to FDG PET

University of California, San Francisco

Phase NA Recruiting
30 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡